上海，2019年6月29日——今日，国际权威科技媒体《麻省理工科技评论》（MIT Technology Review）公布了2019年“50家聪明的公司”（TR 50）评选结果。药明康德通过其独特的开放式医药研发赋能平台，帮助全球客户加快新药研发进程，因此成功入选该权威榜单。

《麻省理工科技评论》是一家具有全球影响力的杰出科技类媒体，2010 年起设立“50家聪明的公司”榜单，每年都会根据“高精尖科技创新和成功商业模式”两个核心指标，从全球范围内评选出最具代表性的公司。该榜单展现了过去一年新兴科技为整个世界所带来的创新变革与突破，已成为全球最权威的商业技术荣誉榜单之一。

“50家聪明的公司”榜单旨在表彰那些能够聪明地将技术创新与商业模式创新有效结合，并取得关键性进展的公司。《麻省理工科技评论》TR50榜单评委会表示：“药明康德创造性地建立了开放式、一体化的医药研发赋能平台，对全球医药研发领域的变革和发展产生了积极影响。”

“感谢《麻省理工科技评论》对药明康德的认可，”药明康德董事长兼首席执行官李革博士表示，“我们的使命是让任何人、任何公司都能够通过药明康德的赋能平台实现新药研发的创新梦想。未来，我们将继续致力于帮助全球客户提升研发效率，让更多新药早日进入市场，造福全球病患。”

关于药明康德

药明康德（股票代码：603259/2359.HK）是国际领先的开放式能力与技术平台公司，为全球制药及医疗器械等领域提供从药物发现、开发到市场化的全方位一体化的实验室研发和生产服务。本着以研究为首任，以客户为中心的宗旨，药明康德通过高性价比、高效率的服务平台帮助全球客户缩短药物及医疗器械研发周期、降低研发成本。药明康德平台涵括小分子药物研发及生产、细胞疗法与基因疗法研发生产、医疗器械测试等，正承载着来自全球30多个国家的3500多家创新合作伙伴的数千个研发创新项目，致力于将最新和最好的医药和健康产品带给全球病患，实现“让天下没有难做的药，难治的病”的梦想。更多信息，请访问公司网站：www.wuxiapptec.com

---

WuXi AppTec Named One of MIT Technology Review’s 50 Smartest Companies

Shanghai, June 29, 2019 – WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review’s 50 Smartest Companies (TR50) for 2019. WuXi was chosen for its dedication in building an open-access R&D enabling platform for companies around the world to discover and develop new medicines for patients efficiently.

MIT Technology Review is one of the world’s preeminent technology publication and has been publishing this prestigious accolade since 2010. The 50 Smartest list was created to recognize companies that “best combine innovative technology with an effective business model.” TR50 demonstrates the innovative breakthroughs and significant impact that emerging technologies bring to the world.

Each year MIT Technology Review identifies 50 companies that are intelligently creating new opportunities by combining important technologies with a business savvy approach. The TR50 judging panel commented, “WuXi pioneered an open-access and integrated R&D platform, enabling thousands of customers to accelerate drug development. They have made a positive impact on innovation in the drug R&D industry globally.”

“It is our honor to be recognized by MIT Technology Review,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “At WuXi, our goal is to build the foundations upon which anyone, and any company, can be empowered to realize their innovation dreams. Collectively, we can continue to improve productivity, and bring new medicines to patients much faster.”

About WuXi AppTec

WuXi AppTec is a leading pharmaceutical and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and medical device testing, the WuXi platform is enabling more than 3,500 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com